As USP28 is frequently deleted in a proportion of melanoma patients, the authors suggested rigosertib as a potential therapeutic strategy for USP28-depleted cells, demonstrating an increased sensitivity of USP28-depleted cells to rigosertib. This evidence concerns the gene USP28 and melanoma.